Skip to main content
. 2018 Jan 8;21(3):247–255. doi: 10.1007/s11102-017-0853-3

Fig. 5.

Fig. 5

a Mean fasting glucose increased during pasireotide treatment (values from 7 patients included in the baseline mean value and s.c. phase, 5 patients for the LAR phase). b Mean HbA1c levels increased during pasireotide treatment (values from 7 patients during s.c. phase and 5 patients during LAR phase)